Quince Therapeutics, Inc. — FY2022 Form 10-K
Reporting period: Fiscal year ended December 31, 2022. The filing was signed March 15, 2023. Quince was a preclinical-stage biopharmaceutical company; it had no approved products and had never generated product-sales revenue.
Business context and strategic direction
Quince acquired Novosteo in May 2022, issued 5.52 million shares in the transaction, and shifted its focus toward Novosteo’s bone-targeting platform and lead candidate NOV004. It changed its name from Cortexyme to Quince Therapeutics and its Nasdaq ticker from CRTX to QNCX in August 2022.
After year-end, Quince announced it would stop internal development of NOV004 and seek a partner or licensee, while prioritizing in-licensing or acquiring clinical-stage assets for rare and debilitating diseases. It also sold its legacy protease-inhibitor portfolio in January 2023.
Financial performance and position
| Metric | FY2022 | FY2021 |
|---|---|---|
| Research and development expense | $25.2 million | $60.8 million |
| General and administrative expense | $26.0 million | $29.5 million |
| Goodwill impairment | $0.8 million | None |
| Operating loss | $52.0 million | $90.3 million |
| Net loss | $51.7 million | $89.9 million |
| Net loss per share, basic and diluted | $1.54 | $3.03 |
| Net cash used in operating activities | $44.0 million | $62.9 million |
No product-sales revenue was reported; the filing says the company had never generated revenue from sales. Actual consolidated revenue is not clearly presented as a separate line item, though the filing describes acquisition-related revenue as immaterial. Gross margin and operating margins are not meaningful for this development-stage business.
At December 31, 2022, cash and cash equivalents were $44.6 million, short-term investments $45.6 million, and long-term investments $3.6 million, totaling $93.8 million. Total assets were $103.9 million; total liabilities were $3.3 million; and stockholders’ equity was $100.6 million. Liabilities included accounts payable, accrued expenses, lease liabilities, and deferred taxes. The filing reports no material borrowings or long-term contractual commitments.
Cash and cash equivalents decreased $25.1 million during 2022. Investing activities provided $18.0 million, including $10.6 million of cash acquired with Novosteo; financing activities provided $0.7 million. Quince said existing capital resources were expected to fund planned operations through at least 2026, excluding costs of in-licensing activities; it also cautioned that assumptions could prove wrong and stated resources were sufficient for at least 12 months from issuance of the financial statements.
Changes, outlook, and material items
- R&D expense fell 58.6%, mainly because the GAIN Phase 2/3 trial of atuzaginstat (COR388) had concluded in 2021. The trial did not meet its co-primary endpoints, and the FDA placed COR388 on full clinical hold in January 2022.
- G&A expense declined 11.9%. The company recorded $0.8 million of non-cash goodwill impairment in 2022; goodwill from the Novosteo acquisition was fully impaired. The $5.9 million NOV004 in-process R&D intangible was not impaired as of year-end, but Quince planned to reassess it following its strategic change.
- In January 2023, Quince transferred COR388, COR588, COR803, and COR852 to Lighthouse Pharmaceuticals. Consideration included 7.5% of Lighthouse’s outstanding common stock and potential product-by-product milestones of up to $150 million, royalties, and certain sublicense income. These contingent payments depend on future development, approvals, and sales and are not assured.
- Quince’s January 2023 restructuring targeted a roughly 47% workforce reduction, with estimated annualized operating-expense savings of about $10 million in 2023, excluding stock compensation and one-time costs. Estimated restructuring costs were $0.6–$0.8 million, mostly cash; additional facility, asset-disposal, or contract-termination costs could arise.
- Management said it expects losses to continue and that additional capital may be needed, particularly to acquire or in-license assets. Financing may be unavailable or dilutive, and development plans could be delayed, reduced, or discontinued.
- Key risks include the lack of a current internally developed clinical-stage candidate, uncertainty in finding partners for NOV004 or new assets, clinical and regulatory failure, dependence on third parties, intellectual-property and licensing risks, and potential impairment or closure costs. Nasdaq had notified the company in December 2022 that its share price was below the $1.00 minimum bid-price requirement.
Investor facts to verify
- Confirm current cash, investment maturities, operating burn, and whether management’s runway estimate includes planned acquisition or in-licensing spending.
- Track whether Quince secures a partner for NOV004 and whether the January 2023 Lighthouse transaction produces any value; the equity stake is in a private company and milestone and royalty proceeds are contingent.
- Review the status and terms of any clinical-stage asset acquisition, including funding needs, dilution, and development plans.
- Check actual restructuring savings and costs, lab-closure and lease obligations, and any further impairment of the NOV004 IPR&D asset.
- Monitor Nasdaq bid-price compliance and any effect on financing access or trading liquidity.
- Note that the independent auditor issued an unqualified opinion on the financial statements; it did not attest to internal control effectiveness. Management reported effective disclosure controls and internal control over financial reporting as of December 31, 2022.